Inclusion Criteria:

- Histologic or cytologic diagnosis of stage IIIB/IV NSCLC

- ECOG PS: 0,1

- Unidimensional or bi-dimensional measurable disease

- Receive prior treatment including first-line platinum-based chemotherapy, standard
second-line chemotherapy and 1 EGF/EGFR inhibitor

- Evidence of disease progression

- Life expectancy >12 weeks

- Neutrophils > 1.5 109/l, Platelets > 100 109/l, Hemoglobin > 9g/dl, Total bilirubin <
1.5 UNL, AST (SGOT) and ALT (SGPT) < 2.5 UNL, Alkaline phosphatases < 5 UNL,
Creatinine < 1 UNL

Exclusion Criteria:

- Pre-existing hemoptysis of a severity > grade 3 by NCI CTCAE criteria within 4 weeks
prior to study entry

- Uncontrolled hypertension

- CHF, angina or arrhythmias

- LVEF < 1 UNL

- Existing a second malignancy within 5 years

- Infected with HIV